JPH04300836A - Hepatic dysfunction preventive agent and functional food having preventive action on hepatic dysfunction - Google Patents
Hepatic dysfunction preventive agent and functional food having preventive action on hepatic dysfunctionInfo
- Publication number
- JPH04300836A JPH04300836A JP3091074A JP9107491A JPH04300836A JP H04300836 A JPH04300836 A JP H04300836A JP 3091074 A JP3091074 A JP 3091074A JP 9107491 A JP9107491 A JP 9107491A JP H04300836 A JPH04300836 A JP H04300836A
- Authority
- JP
- Japan
- Prior art keywords
- tea
- extract
- hepatic dysfunction
- tea leaves
- functional food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003449 preventive effect Effects 0.000 title claims abstract description 13
- 235000013376 functional food Nutrition 0.000 title claims abstract description 11
- 208000027700 hepatic dysfunction Diseases 0.000 title abstract 6
- 239000000284 extract Substances 0.000 claims abstract description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 31
- 238000000605 extraction Methods 0.000 claims abstract description 11
- 239000002904 solvent Substances 0.000 claims abstract description 11
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 208000019423 liver disease Diseases 0.000 claims description 9
- 230000005976 liver dysfunction Effects 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 4
- 241001122767 Theaceae Species 0.000 claims 4
- 244000269722 Thea sinensis Species 0.000 abstract description 66
- 235000013616 tea Nutrition 0.000 abstract description 62
- 230000000694 effects Effects 0.000 abstract description 29
- 235000009569 green tea Nutrition 0.000 abstract description 5
- 235000006468 Thea sinensis Nutrition 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 238000001035 drying Methods 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 235000020279 black tea Nutrition 0.000 abstract description 2
- 229930014626 natural product Natural products 0.000 abstract description 2
- 235000020333 oolong tea Nutrition 0.000 abstract description 2
- 238000005096 rolling process Methods 0.000 abstract description 2
- 238000010025 steaming Methods 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 1
- 206010067125 Liver injury Diseases 0.000 description 17
- 231100000234 hepatic damage Toxicity 0.000 description 17
- 230000008818 liver damage Effects 0.000 description 17
- 235000019441 ethanol Nutrition 0.000 description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 11
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000000469 ethanolic extract Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 108010042606 Tyrosine transaminase Proteins 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 3
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 3
- 235000005487 catechin Nutrition 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000003228 microsomal effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 231100000354 acute hepatitis Toxicity 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- CBOJBBMQJBVCMW-NQZVPSPJSA-N (2r,3r,4r,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@@H](O)[C@H](O)CO CBOJBBMQJBVCMW-NQZVPSPJSA-N 0.000 description 1
- QKPLRMLTKYXDST-WNFIKIDCSA-N (2s,3r,4r,5r,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;hydrochloride Chemical compound Cl.N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O QKPLRMLTKYXDST-WNFIKIDCSA-N 0.000 description 1
- 206010071238 Binge Drinking Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000209507 Camellia Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940092665 tea leaf extract Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【０００１】0001
【産業上の利用分野】本発明は、水、アルコールまたは
これらの混合液を溶媒として茶葉から抽出した茶抽出物
を有効成分とする肝機能障害予防剤もしくは機能性食品
に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an agent for preventing liver dysfunction or a functional food containing as an active ingredient a tea extract extracted from tea leaves using water, alcohol, or a mixture thereof as a solvent.
【０００２】0002
【従来の技術】近年、各種の成人病の中でも、特に肝臓
病に起因する死亡が、がん、心臓疾患、脳血管疾患につ
いで多い。肝障害は、臨床的には急性肝炎、慢性肝炎、
脂肪肝、肝硬変等に区分され、原因的には、アルコール
性、ウイルス性等に分けられる。通常急性肝炎は、ウイ
ルスに起因するものが多く、また、酒の飲みすぎ等によ
って、脂肪肝、更には肝硬変が引き起こされるといわれ
ている。BACKGROUND OF THE INVENTION In recent years, among various adult diseases, liver disease is the third most common cause of death, following cancer, heart disease, and cerebrovascular disease. Clinically, liver damage is classified as acute hepatitis, chronic hepatitis,
It is classified into fatty liver, liver cirrhosis, etc., and the cause is divided into alcoholic, viral, etc. Acute hepatitis is usually caused by viruses, and it is said that excessive drinking of alcohol causes fatty liver and even cirrhosis.
【０００３】肝障害は、殆ど自覚症状がなく、軽い病変
では気付かれない事が多い。そこで、肝障害の早期発見
のために、通常血液中のＧＯＴ，ＧＰＴを測定する肝機
能検査が行れている。[0003] Liver damage has almost no subjective symptoms, and mild lesions often go unnoticed. Therefore, for early detection of liver damage, liver function tests that measure GOT and GPT in the blood are usually performed.
【０００４】このように肝障害は、自覚症状等を伴わな
いことが多く、発見が遅れて手遅れになったり、軽度の
肝障害の場合でも、回復には相当の日数を要するなど、
腎障害等と並んでやっかいな疾病の一つである。従って
、肝障害の予防や治療について、各方面から数多くの研
究や検討がなされている。[0004] As described above, liver damage often does not cause any subjective symptoms, so it may not be discovered until it is too late, or even in the case of mild liver damage, it may take a considerable number of days to recover.
It is one of the troublesome diseases along with kidney disorders. Therefore, numerous studies and studies have been conducted from various fields regarding the prevention and treatment of liver disorders.
【０００５】[0005]
【発明が解決しようとする課題】肝障害予防のための日
常の生活における対策としては、■ 過労を避ける。
■ バランスよい食品の摂取。■ アルコールの暴
飲を慎む。■ 肝障害の危惧のある薬品の服用を避け
る。等があげられる。しかしながら、適切な食生活、規
則正しい生活を心掛けて、これらの対策を保持するよう
自ら管理することは、現実的には相当難しく、さらに自
覚症状を伴わないため管理をより困難にしている。[Problems to be Solved by the Invention] Measures in daily life to prevent liver damage include: ■ Avoid overwork. ■ Consume well-balanced foods. ■ Refrain from binge drinking alcohol. ■ Avoid taking drugs that may cause liver damage. etc. can be mentioned. However, it is actually quite difficult to manage oneself to maintain these measures by keeping an appropriate diet and a regular lifestyle in mind, and the fact that the disease does not cause any subjective symptoms makes management even more difficult.
【０００６】また、高血圧やコレステロールを抑える薬
、インフルエンザのワクチンのように疾病によっては予
防に極めて効果的な薬品があるが、肝障害の予防剤又は
予防食品などで十分な効果を示すものは未だ見られない
。[0006] In addition, although there are drugs that are extremely effective in preventing some diseases, such as drugs to suppress high blood pressure and cholesterol and vaccines for influenza, there are still no preventive drugs or preventive foods for liver damage that are sufficiently effective. can not see.
【０００７】一方、茶は古くより保健と延命の妙薬とし
て知られている。その薬効としてカフェイン効果、カテ
キン効果、ビタミンＣ効果などが良く知られている。ま
た、茶の成分を分画して得られるカテキン類に特に薬理
効能のあることが知られている。茶の効果はこれらの個
々の効果による分画成分の効果によることはもちろんで
あるが、茶または茶抽出物に含まれる全ての成分による
総合的な効果が茶の効果として表れるものと考えられる
。On the other hand, tea has been known since ancient times as an elixir for health and prolonging life. Its medicinal effects include caffeine effects, catechin effects, and vitamin C effects. In addition, catechins obtained by fractionating tea components are known to have particular pharmacological efficacy. The effects of tea are of course due to the effects of these individual fractionated components, but it is thought that the overall effect of all the components contained in tea or tea extract appears as the effect of tea.
【０００８】そこで、本発明の目的は、天然物由来の安
全性の高い茶葉を原料として、人体に危険な化学薬品を
用いることなく、単に水あるいはアルコールで抽出した
抽出物を用いて、優れた肝障害予防剤、治療剤、あるい
は肝障害予防、治療作用を有する機能性食品を提供する
ことにある。[0008] Therefore, the object of the present invention is to use highly safe tea leaves derived from natural products as a raw material, without using chemicals dangerous to the human body, and by simply using an extract extracted with water or alcohol. The purpose of the present invention is to provide a preventive or therapeutic agent for liver damage, or a functional food that has preventive or therapeutic effects on liver damage.
【０００９】[0009]
【課題を解決するための手段】本発明者等は、茶葉から
水、又はアルコール等で抽出した茶抽出物の薬理作用に
ついて鋭意研究を重ねた結果、茶抽出物が肝障害予防や
治療に有効であることを見出し、本発明を完成するに至
った。[Means for Solving the Problems] As a result of extensive research into the pharmacological effects of tea extracts extracted from tea leaves with water or alcohol, the present inventors have found that tea extracts are effective in preventing and treating liver disorders. The present invention was completed based on this discovery.
【００１０】すなわち、本発明は、茶葉を水、アルコー
ル又はこれらの混合溶液を抽出溶媒として抽出した茶抽
出物を有効成分とする肝機能障害予防剤、或いは前記茶
抽出物を含有してなる肝機能障害予防作用を有する機能
性食品である。[0010] That is, the present invention provides a liver function disorder preventive agent containing a tea extract obtained by extracting tea leaves using water, alcohol, or a mixed solution thereof as an extraction solvent, or a liver function disorder prevention agent containing the tea extract. It is a functional food that has the effect of preventing functional disorders.
【００１１】本発明における茶抽出物は、ツバキ科の常
緑低木Ｔｈｅｓ ＳｉｎｅｓｉｓＬ．の葉を水あるい
は人体に無害なアルコールもしくはこれらの混合溶液で
抽出する。これらは、生の葉部を使用してもよく、また
葉部を乾燥して用いてもよく、さらに葉部を発酵させあ
るいは発酵させることなく蒸成し、揉稔、乾燥を行った
ものを用いてもよい。このようなものとして緑茶、煎茶
、ほうじ茶、ウーロン茶、紅茶等がある。The tea extract in the present invention is derived from Thes Sinesis L., an evergreen shrub of the Camellia family. Extract the leaves with water, alcohol that is harmless to the human body, or a mixed solution of these. These can be made by using fresh leaves, dried leaves, or by fermenting the leaves or steaming them without fermenting them, rolling them, and drying them. May be used. Examples of such tea include green tea, sencha, hojicha, oolong tea, and black tea.
【００１２】抽出は、例えば乾燥した茶葉１００重量部
に対し溶媒５００〜５０００重量部を加えて行う。溶媒
としては、水、温湯、熱湯、あるいはエタノールもしく
はその含水物が用いられ、乾燥した茶葉を前記溶媒に浸
漬するかあるいは加熱下で３分間〜１０時間抽出を行う
ことが望ましい。得られた抽出液は、抽出溶剤を除去し
て濃縮する。濃縮は、前記抽出液を茶抽出成分が３０〜
５０ｗｔ％程度になるまで濃縮する。なお、乾燥した葉
１００重量部は生葉約５００重量部に相当する。また、
アルコール抽出液の場合濃縮する前後に、活性炭、酸性
白土あるいは硅藻土等を用いて不必要な成分を吸着除去
し、濃縮液を脱色してもよい。Extraction is carried out, for example, by adding 500 to 5,000 parts by weight of a solvent to 100 parts by weight of dried tea leaves. As the solvent, water, warm water, boiling water, ethanol or a water content thereof is used, and it is preferable to immerse the dried tea leaves in the solvent or perform extraction under heating for 3 minutes to 10 hours. The obtained extract is concentrated by removing the extraction solvent. Concentration involves converting the extract into a tea extract with a content of 30 to 30%.
Concentrate to about 50 wt%. Note that 100 parts by weight of dried leaves corresponds to about 500 parts by weight of fresh leaves. Also,
In the case of an alcoholic extract, the concentrated liquid may be decolorized by adsorbing and removing unnecessary components using activated carbon, acid clay, diatomaceous earth, or the like before or after concentration.
【００１３】さらに、濃縮液を蒸発乾固したりあるいは
凍結乾燥し、粉末としてもよい。特に抽出液を活性炭で
処理し、凍結乾燥を行うと得られる製品の保存中の変色
を防止することができる。本発明では得られた濃縮液ま
たは粉末が茶抽出物として用いられる。これはそのまま
用いてもよく、あるいはこれらをドリンク剤、錠剤、散
剤、顆粒剤、カプセル剤等としたものを用いてもよい。
さらに、精製水に溶解して用いてもよく、またこれらを
飲食品原料に添加して用いてもよい。添加量としては１
日当たり粉末の場合１，０００〜３，０００ｍｇの濃縮
液の場合３〜１０ｇを摂取するようにするとよい。飲食
品としては、例えば、ジュース、酒類、ビール等の飲料
、麺、パン、米飯、ビスケット等の穀類加工品、ソーセ
ージ、ハム、かまぼこ等の練製品、バター、ヨーグルト
等の乳製品、チューインガム、キャンデー等の菓子、ふ
りかけ、調味料等が用いられ、これらの製造の適宜の段
階で必要量添加することができる。Furthermore, the concentrate may be evaporated to dryness or freeze-dried to form a powder. In particular, when the extract is treated with activated carbon and freeze-dried, discoloration of the resulting product during storage can be prevented. In the present invention, the obtained concentrate or powder is used as a tea extract. These may be used as they are, or they may be prepared into drinks, tablets, powders, granules, capsules, etc. Furthermore, they may be used after being dissolved in purified water, or they may be added to raw materials for food and drink products. The amount added is 1
It is recommended to take 1,000 to 3,000 mg of powder per day, and 3 to 10 g of concentrated liquid per day. Examples of food and beverages include beverages such as juice, alcoholic beverages, and beer; processed grain products such as noodles, bread, cooked rice, and biscuits; pastured products such as sausages, ham, and kamaboko; dairy products such as butter and yogurt; chewing gum and candy. Sweets, furikake, seasonings, etc. are used, and the necessary amount can be added at an appropriate stage of their production.
【００１４】本発明における茶抽出物は、前記したよう
に３分〜１０時間抽出され、茶抽出物濃度３０〜５０ｗ
ｔ％程度に濃縮されるかあるいは乾燥固化又は粉末化さ
れたものであって、このような長時間抽出が行われ、か
つ濃縮されている点で通常の茶飲料とは明確に相違する
。[0014] The tea extract in the present invention is extracted for 3 minutes to 10 hours as described above, and the tea extract concentration is 30 to 50 w.
It is concentrated to about 100%, dried solidified, or powdered, and is clearly different from ordinary tea beverages in that it is extracted over a long period of time and is concentrated.
【００１５】本発明における肝障害予防剤は、前記した
ように濃縮液そのままあるいはドリンク剤、錠剤、散剤
、顆粒剤、カプセル剤等の形として経口的に投与される
。これらの剤の製造は、茶抽出物濃縮液あるいは粉末に
増量剤、バインダー、崩壊剤、矯味剤、矯臭剤、着色剤
等をその製剤の剤型に応じて加えて従来知られている慣
用の製剤の製造法を用いて製造するとよい。投与量は、
成人に対し粉末の場合１日約１，０００〜３，０００ｍ
ｇを、また濃縮液の場合３〜１０ｇを１日数回に分けて
投与する。この投与量は、日常飲用しているお茶の数倍
量に相当する。この抽出物は常用されている茶葉の成分
であるので毒性はなく、従って上記投与量を超えて投与
しても何等支障はない。このようにすると肝機能障害を
未然に防げるとともに、その治療にも有用である。[0015] As described above, the liver damage preventive agent of the present invention is administered orally as a concentrate or in the form of a drink, tablet, powder, granule, capsule, or the like. These preparations are manufactured by adding fillers, binders, disintegrants, flavoring agents, flavoring agents, coloring agents, etc. to tea extract concentrate or powder, depending on the dosage form of the preparation. It is preferable to manufacture the drug using a manufacturing method for pharmaceutical preparations. The dosage is
Approximately 1,000 to 3,000 m per day in the case of powder for adults
g or, in the case of a concentrated solution, 3 to 10 g in divided doses several times a day. This dose is equivalent to several times the amount of tea we drink daily. Since this extract is a component of tea leaves that is commonly used, it is not toxic, and therefore there is no problem in administering it in doses exceeding the above-mentioned dosage. In this way, liver dysfunction can be prevented and also useful for its treatment.
【００１６】また、本発明における機能性食品は、前記
したように本発明における茶抽出物を添加した飲食品で
あって肝機能障害の予防あるいは治療に有用である。こ
のように、茶抽出物を薬品や機能性食品のかたちで、ま
たは単に清水に溶かして摂取するだけでも、血液中のＧ
ＯＴ値の上昇を抑え、肝機能障害の予防に有効に用いる
ことができる。すなわち、肝炎、脂肪肝、肝硬変等の発
症を防ぎ、これらの症状を軽減乃至治療することができ
る。[0016]Furthermore, the functional food of the present invention is a food or drink to which the tea extract of the present invention is added, as described above, and is useful for the prevention or treatment of liver dysfunction. In this way, ingesting tea extract in the form of medicine or functional food, or simply dissolving it in clean water, can increase the amount of G in the blood.
It suppresses the increase in OT value and can be effectively used to prevent liver dysfunction. That is, the onset of hepatitis, fatty liver, liver cirrhosis, etc. can be prevented, and these symptoms can be alleviated or treated.
【００１７】本発明についてさらに詳細かつ具体的に説
明する。
（１）茶抽出物の製造
乾燥茶葉５０ｇを７０℃の温水１０００ｍｌに５分間浸
出操作を行い、濾過した。濾液のｐＨは約５．９であっ
た。この濾液を直ちに凍結乾燥した。こうして緑色微粉
末状の温水による茶抽出物１２ｇを得た（抽出物１ｇ当
たり煎茶４．２ｇのなかの抽出成分を含有）。The present invention will be explained in more detail and specifically. (1) Production of tea extract 50 g of dried tea leaves was leached in 1000 ml of 70° C. hot water for 5 minutes and filtered. The pH of the filtrate was approximately 5.9. This filtrate was immediately lyophilized. In this way, 12 g of a hot water tea extract in the form of a fine green powder was obtained (1 g of the extract contained extracted components of 4.2 g of Sencha green tea).
【００１８】また、乾燥茶葉１００ｇを９５％エタノー
ル１０００ｍｌに浸漬し、８０℃で３時間抽出した。得
られた抽出液を濾過して茶葉を除去した後、茶葉抽出物
濃度が約５ｗｔ％程度になる迄濃縮した。該濃縮液に清
水２１０ｍｌ及び活性炭８５ｇを入れ、約６０℃で３時
間撹拌混合した。そして、活性炭を濾過除去した後、エ
タノールと一部の水を蒸発除去して、茶成分濃度約５０
％に濃縮したところ、濃褐色の水溶液３０ｇを得た。Further, 100 g of dried tea leaves was immersed in 1000 ml of 95% ethanol and extracted at 80° C. for 3 hours. The obtained extract was filtered to remove tea leaves, and then concentrated until the tea leaf extract concentration was about 5 wt%. 210 ml of fresh water and 85 g of activated carbon were added to the concentrated solution, and the mixture was stirred and mixed at about 60° C. for 3 hours. After removing the activated carbon by filtration, ethanol and some water are removed by evaporation, resulting in a tea component concentration of approximately 50%.
%, 30 g of a dark brown aqueous solution was obtained.
【００１９】このようにして得た温水抽出物、及びエタ
ノール抽出物の成分分析値（ｗｔ％）を、表１に示す。Table 1 shows the component analysis values (wt%) of the hot water extract and ethanol extract thus obtained.
【００２０】[0020]
【表１】
温水抽出 エタ
ノール抽出成 分 名
凍結乾燥物
精製濃縮液 水分
１．２
５３．６ 脂質
０．６ ０．３
灰分
１１．５
１．３ 全窒素
３．５
１．１ 無水カフェイン
７．５
２．１ タンニン
３１．
８ ２１．４ エピ
カテキン
３．３ １．４
エピカテキンガレート
２．５ ２．１
エピガロカテキン
１１．０ ５．９
エピガロカテキンガレート １５
．０ ８．９ フラ
ボノイド
ケンフェロール
０．８５ ０
．０４ ケルセチン
０．７４
０．１５ ミリセチン
０．２９
０．１０ 全糖
１２．
９ １０．９ 水溶
性多糖類
２．４ ０．０
１ 全アスコルビン酸
０．８７
── テアニン
２．１
０．５ 総クロロフィル
１５．９＊
── カルシウム
０．０６ ０．０１
ナトリウム
０．０２ ０
．０４ カリウム
５．５
０．６２ マグネシウム
０．０４
０．０２
（単位ｗｔ％
、ただし＊はｍｇ／１００ｇ）[Table 1]
Hot water extraction Ethanol extraction component name
Freeze-dried product
Purified concentrate water
1.2
53.6 Lipids
0.6 0.3
ash
11.5
1.3 Total nitrogen
3.5
1.1 Anhydrous caffeine
7.5
2.1 Tannins
31.
8 21.4 Epicatechin
3.3 1.4
epicatechin gallate
2.5 2.1
epigallocatechin
11.0 5.9
Epigallocatechin gallate 15
．． 0 8.9 Flavonoid Kaempferol
0.85 0
．． 04 Quercetin
0.74
0.15 Myricetin
0.29
0.10 total sugar
12.
9 10.9 Water-soluble polysaccharides
2.4 0.0
1 Total ascorbic acid
0.87
── Theanine
2.1
0.5 total chlorophyll
15.9*
── Calcium
0.06 0.01
sodium
0.02 0
．． 04 Potassium
5.5
0.62 Magnesium
0.04
0.02
(Unit: wt%
, however, * indicates mg/100g)
【００２１】（２）茶抽
出物の肝障害予防評価試験（ｉ）実験動物
一群６匹のＷｉｓｔａｒ系雌性ラット（１０週令、体重
１５０〜１６０ｇ；Ｊａｐａｎ ＳＬＣ（株）製）を
８群用意し、生理食塩液のみの投与する第Ｉ群と、肝障
害誘発化学物質の一つであるガラクトサミンを投与する
第ＩＩ〜Ｖ群とに分け、さらに第ＩＩＩ 〜Ｖ群には茶
抽出物を投与し、投与する茶抽出物が温水抽出によるも
のである場合に、添字ａを付し、エタノール抽出物の場
合には添字ｂを付した。(2) Test for evaluating the prevention of liver damage using tea extract (i) Experimental animals Eight groups of 6 female Wistar rats (10 weeks old, weight 150-160 g; manufactured by Japan SLC Co., Ltd.) were prepared. The animals were divided into Group I, in which only physiological saline was administered, and Groups II to V, in which galactosamine, a chemical substance that induces liver damage, was administered, and Groups III to V were further administered tea extract. , the suffix a was given if the tea extract administered was by hot water extraction, and the suffix b was given if it was an ethanolic extract.
【００２２】（ｉｉ）ガラクトサミン投与液の調製及び
投与量の決定
ガラクトサミン投与液は、Ｄ（＋）ガラクトサミン塩酸
塩（ｇａｌａｃｔｏｓａｍｉｎｅ ｈｙｄｒｏｃｈｏ
ｌｉｄｅ）３．８ｇを、生理食塩液１１ｍｌに溶解し、
１Ｎ ＮａＯＨ水溶液で中和して投与液（注射液）を
調整した。(ii) Preparation of galactosamine administration solution and determination of dosage The galactosamine administration solution consists of D(+)galactosamine hydrochloride (galactosamine hydrochloride).
3.8 g of 3.8 g of Lide) were dissolved in 11 ml of physiological saline,
An administration solution (injection solution) was prepared by neutralizing with 1N NaOH aqueous solution.
【００２３】ガラクトサミンの投与量を、４００ｍｇ／
ｋｇ、７００ｍｇ／ｋｇ、及び１０００ｍｇ／ｋｇの３
レベルで２４時間後のＧＯＴ、ＧＰＴ活性の変化量を求
めた予備実験の結果に基づき、肝障害を起こすに十分な
ガラクトサミンの投与量を７００ｍｇ／ｋｇに決定した
。[0023] The dosage of galactosamine was 400mg/
kg, 700mg/kg, and 1000mg/kg
Based on the results of a preliminary experiment in which the amount of change in GOT and GPT activity after 24 hours was determined, the dose of galactosamine sufficient to cause liver damage was determined to be 700 mg/kg.
【００２４】（ｉｉｉ）実験手順
各群への茶抽出物及びガラクトサミン等の投与の詳細及
び評価分析用サンプルの採取は次の通り。(iii) Experimental Procedures Details of administration of tea extract, galactosamine, etc. to each group and collection of samples for evaluation and analysis are as follows.
【００２５】■投与の詳細
ラットへの投与量は表２に示すとおりである。茶抽出物
は、ガラクトサミン投与１５時間前、投与時、８時間後
、２４時間後、及び３２時間後の計５回、表２記載の量
を強制的に経口投与した。第Ｉ群への生理食塩水は、第
ＩＩ〜Ｖ群へのガラクトサミン投与と同じタイミングで
１回投与した。なお、温水抽出物（粉体）は、清水に溶
解させて投与した。また実験中の給餌は、固形飼料を自
由に摂取させた。エタノール抽出物の投与レベルは、タ
ンニン量が温水抽出物と同じ量となるようにした。■Details of Administration The doses administered to rats are shown in Table 2. The tea extract was forcibly administered orally in the amounts listed in Table 2 five times in total: 15 hours before, at the time of, 8 hours after, 24 hours after, and 32 hours after galactosamine administration. Physiological saline to Group I was administered once at the same timing as galactosamine administration to Groups II to V. Note that the hot water extract (powder) was dissolved in clear water and administered. During the experiment, the animals were given solid feed ad libitum. The dosage level of the ethanol extract was such that the amount of tannins was the same as the hot water extract.
【００２６】[0026]
【表２】[Table 2]
【００２７】■血液サンプルの採取、解剖評価に必要な
血液及び臓器摘出は、各ラットにつき次のようにして行
った。ガラクトサミン投与時を基準として（１）血液を
８時間後及び２４時間後の２回は尾静脈より約０．６ｃ
ｃ採取し、
（２）血液を４８時間後には、腹部大動脈より約３．０
ｃｃ採取した。
（３）４８時間後の採血後直ちに解剖し、肝臓は各種の
測定を行うまで−８０℃にて保存した。
なお、茶抽出物を投与しない第Ｉ群及び第ＩＩ群の採血
は、茶抽出物投与の場合と全く同じ採取時間に、同じよ
うにして行った。また、全てのラットは、各採血前１２
時間の間絶食させた。[0027] Collection of blood samples and extraction of blood and organs necessary for anatomical evaluation were performed for each rat as follows. Based on the time of galactosamine administration (1) Blood was collected twice from the tail vein at 8 hours and 24 hours later by approximately 0.6c.
(2) After 48 hours, the blood was collected from the abdominal aorta to approximately 3.0
CC was taken. (3) Immediately after blood collection 48 hours later, the animals were dissected and the livers were stored at -80°C until various measurements were taken. In addition, blood collection for Group I and Group II to which no tea extract was administered was performed at exactly the same collection time and in the same manner as in the case of tea extract administration. Additionally, all rats were tested 12 hours before each blood draw.
Fasted for an hour.
【００２８】以上の一連の手順を示すと以下のとおりで
ある。The above series of steps are as follows.
【００２９】（ｉｖ） 測定項目と測定方法肝障害に関
するパラメータのうち、採取した血液から分離した血清
より、肝機能を示すＧＯＴ、ＧＰＴ及びＡＬＰ活性を測
定試験キット（和光純薬製、型番等）を用いて測定した
。また、摘出した肝臓から肝代謝酵素活性について、血
液中の遊離型コレステロールをエステル型に変換する酵
素であるＬＣＡＴの活性を国友らの方法（Ｊａｐａｎ
Ｊ．Ｐｈａｒｍａｃｏｌ，３４，１５３−１５８，１
９８４）で、典型的薬物代謝酵素である肝ミクロソーム
Ｐ−４５０を大村らの方法（Ｊ，Ｂｉｏｌ．Ｃｈｅｍ．
，２３９，２３７０−２３７８，１９６４）で、血液中
の糖質コルチコイドのマーカー酵素といわれるチロシン
トランスアミナーゼ（ＴＴＡ）活性をＴｈｏｍａｓらの
方法（Ａｎａｌ．Ｂｉｏｃｈｅｍ．，１６，３９５−４
０１，１９６６）で測定した。(iv) Measurement items and methods Among parameters related to liver damage, GOT, GPT, and ALP activities, which indicate liver function, are measured from serum separated from collected blood Test kit (manufactured by Wako Pure Chemical Industries, Ltd., model number, etc.) Measured using In addition, the activity of LCAT, an enzyme that converts free cholesterol in the blood into an ester form, was measured using the method of Kunitomo et al. (Japan).
J. Pharmacol, 34, 153-158, 1
984), liver microsomal P-450, a typical drug-metabolizing enzyme, was synthesized by the method of Omura et al. (J, Biol. Chem.
, 239, 2370-2378, 1964), the activity of tyrosine transaminase (TTA), which is said to be a marker enzyme for glucocorticoids in the blood, was measured using the method of Thomas et al. (Anal. Biochem., 16, 395-4).
01, 1966).
【００３０】（ｖ）統計処理
得られた測定値は平均値±標準誤差で表示し、第ＩＩ群
（ＧＡ投与群）との測定値間の有意差検定にはＳｔｕｄ
ｅｎｔ’ｓ ｔ−ｔｅｓｔを適用した。(v) Statistical processing The obtained measured values are expressed as the mean value ± standard error, and a significant difference between the measured values with Group II (GA administration group) was tested using Stud.
ent's t-test was applied.
【００３１】（５）実験結果
実験結果を図１〜図６に示す。図１−（ａ）、図１−（
ｂ）は、それぞれ温水抽出物及びエタノール抽出物投与
での、ＧＯＴ活性の変化を示すものである。温水抽出物
及びエタノール抽出物両投与群ともガラクトサミン（Ｇ
Ａ）投与２４時間後において用量依存的な抑制効果を示
し、特に最高用量投与の第Ｖ群においては有意な抑制を
示している。また４８時間後でも減少傾向を維持してい
た。(5) Experimental Results Experimental results are shown in FIGS. 1 to 6. Figure 1-(a), Figure 1-(
b) shows changes in GOT activity upon administration of warm water extract and ethanol extract, respectively. Galactosamine (G
A) A dose-dependent suppressive effect was shown 24 hours after administration, and particularly significant suppression was shown in Group V, which was administered at the highest dose. Moreover, the decreasing trend was maintained even after 48 hours.
【００３２】図２−（ａ）、図２−（ｂ）は、それぞれ
温水抽出物及びエタノール抽出物投与での、ＧＰＴ活性
の変化を示すものである。ＧＯＴの結果と殆ど全く同じ
傾向が認められる。FIGS. 2-(a) and 2-(b) show changes in GPT activity upon administration of warm water extract and ethanol extract, respectively. Almost the same tendency as the GOT results is observed.
【００３３】図３−（ａ）、図３−（ｂ）は、それぞれ
温水抽出物及びエタノール抽出物投与での、ＡＬＰ活性
の変化を示すものである。温水、エタノール両投与群と
もＧＡ投与２４及び４８時間後において抑制効果が認め
られる。FIGS. 3-(a) and 3-(b) show changes in ALP activity upon administration of warm water extract and ethanol extract, respectively. Suppressive effects were observed 24 and 48 hours after GA administration in both warm water and ethanol administration groups.
【００３４】図４−（ａ）は、温水抽出物投与でのＬＣ
ＡＴの活性の変化を示す。茶抽出物は、ＬＣＡＴ活性を
抑制する傾向を示している。FIG. 4-(a) shows LC after administration of hot water extract.
It shows changes in AT activity. Tea extracts have shown a tendency to suppress LCAT activity.
【００３５】図５−（ａ）及び図６−（ａ）は、温水抽
出物投与で、４８時間後の肝ミクロゾームＰ−４５０及
びチロシントランスアミナーゼ（ＴＴＡ）活性の比較を
それぞれ示す。茶抽出物の投与はＰ−４５０を抑制し、
ＴＴＡ活性を増強する傾向を示す。FIGS. 5-(a) and 6-(a) show a comparison of liver microsomal P-450 and tyrosine transaminase (TTA) activities 48 hours after administration of the warm water extract, respectively. Administration of tea extract suppresses P-450 and
Shows a tendency to enhance TTA activity.
【００３６】これらの結果から、茶の温水抽出物及びエ
タノール抽出物は用量依存的に肝障害を予防する効果が
あると認められる。茶の抽出物中のタンニン類のカテキ
ンに加えて、その他のフラボノイド、ビタミンＣ等の成
分との相互作用として肝障害を抑制していると判断され
る。また、投与量は、温水抽出物の場合５０〜２００ｍ
ｇ／Ｋｇ、及びエタノール抽出物の場合７５〜３００ｍ
ｇ／ｋｇの範囲で充分効果が得られる。From these results, it is recognized that the hot water extract and ethanol extract of tea are effective in preventing liver damage in a dose-dependent manner. In addition to catechin, a tannin in tea extract, it is thought that liver damage is suppressed through interaction with other components such as flavonoids and vitamin C. In addition, the dosage is 50-200m for hot water extract.
g/Kg, and 75-300m for ethanol extracts.
A sufficient effect can be obtained within the range of g/kg.
【００３７】次に本発明の実施例を示す。Next, examples of the present invention will be shown.
【実施例１】蒸留水１０００ｍｌを７０℃に加熱し、こ
れに乾燥茶葉（市販品）５０ｇを二重にガーゼに包み、
投入し撹拌しながら５分間抽出した。抽出液を外部を氷
で冷却しながら２０℃まで冷却した。ガーゼをしぼって
茶葉中に含まれている水を回収した。この抽出液を真空
濾過器で濾過し、約８２０ｍｌの濾液を得た。次に、こ
の濾過を−５５℃に急速に冷却して凍結し、０．００１
気圧で脱水乾燥を行って、約１２ｇの粉末（水分含有量
約１〜１．５％）を得た。[Example 1] 1000 ml of distilled water was heated to 70°C, 50 g of dried tea leaves (commercially available) was wrapped in gauze, and
and extracted for 5 minutes while stirring. The extract was cooled to 20°C while being externally cooled with ice. The water contained in the tea leaves was collected by squeezing the gauze. This extract was filtered using a vacuum filter to obtain about 820 ml of filtrate. This filtration was then rapidly cooled to -55°C and frozen to 0.001
Dehydration and drying was carried out under atmospheric pressure to obtain about 12 g of powder (water content about 1-1.5%).
【００３８】[0038]
【実施例２】茶葉１００ｇを９５％エタノール１０００
ｍｌに浸漬し、３時間抽出した。抽出後濾過して茶葉を
除去し、エタノールを蒸発し、抽出物濃度を５．５ｗｔ
％に濃縮した。該濃縮液に清水２１０ｍｌ及び活性炭８
５ｇを入れ、約６０℃で３時間撹拌混合した。そして、
活性炭を濾過除去した後、エタノールと一部の水を蒸発
除去して、茶成分濃度約５０％に濃縮したところ、濃褐
色の水溶液３０ｇを得た。[Example 2] 100g of tea leaves in 95% ethanol 1000
ml and extracted for 3 hours. After extraction, filter the tea leaves, evaporate the ethanol, and reduce the extract concentration to 5.5wt.
It was concentrated to %. Add 210 ml of fresh water and 8 ml of activated carbon to the concentrate.
5 g was added and stirred and mixed at about 60° C. for 3 hours. and,
After removing the activated carbon by filtration, ethanol and a portion of the water were removed by evaporation and concentrated to a tea component concentration of about 50%, yielding 30 g of a dark brown aqueous solution.
【００３９】[0039]
【実施例３】実施例１で得られた凍結乾燥粉末２０重量
部に、乳糖６５重量部、デキストリン１０重量部、タル
ク７５重量部及び水を適量加え常法に従って錠剤とした
。Example 3 To 20 parts by weight of the freeze-dried powder obtained in Example 1, 65 parts by weight of lactose, 10 parts by weight of dextrin, 75 parts by weight of talc, and appropriate amounts of water were added to form tablets according to a conventional method.
【００４０】[0040]
【実施例４】実施例１で得られた凍結乾燥粉末１０ｇと
蔗糖１０ｇ、水あめ６４ｇ、有機酸１ｇ、香料０．２ｇ
及び水少量とを混合し、常法により加熱冷却し、キャン
ディを製造した。[Example 4] 10 g of the freeze-dried powder obtained in Example 1, 10 g of sucrose, 64 g of starch syrup, 1 g of organic acid, and 0.2 g of fragrance
and a small amount of water were mixed and heated and cooled in a conventional manner to produce candy.
【００４１】[0041]
【実施例５】実施例２で得られた濃褐色液３ｇと蔗糖１
５ｇ、蜂蜜１ｇ、ソルビトール０．３ｇ、アミノ酸２０
ｍｇ、ビタミン類３６０ｍｇ、有機酸１８０ｍｇ、香料
１００ｍｇを混合し、常法により加熱冷却し、キャンデ
ィを製造した。[Example 5] 3 g of dark brown liquid obtained in Example 2 and 1 sucrose
5g, honey 1g, sorbitol 0.3g, amino acids 20
mg, 360 mg of vitamins, 180 mg of organic acid, and 100 mg of fragrance were mixed and heated and cooled in a conventional manner to produce candy.
【００４２】[0042]
【発明の効果】本発明は、茶葉から水又はアルコール、
もしくはこれらの混合液を抽出溶媒として抽出した茶抽
出物を有効成分とする肝機能障害予防剤又は茶抽出物を
添加した機能性食品であるので、簡単な抽出操作で得ら
れ、副作用がなく、肝機能の低下を予防するものであり
、薬剤、或いは機能性食品として極めて有用なものであ
る。[Effect of the invention] The present invention provides water or alcohol from tea leaves.
Alternatively, it is a liver function disorder preventive agent containing tea extract extracted from a mixture of these as an extraction solvent or a functional food containing tea extract, which can be obtained by a simple extraction procedure and has no side effects. It prevents a decline in liver function and is extremely useful as a drug or functional food.
【図１】（ａ）温水抽出物を投与した場合、ＧＡ（ガラ
クトサミン）投与後の経過時間に伴なうＧＯＴの変化を
示す。
（ｂ）エタノール抽出物を投与した場合、ＧＡ投与後の
経過時間に伴なうＧＯＴの変化を示す。FIG. 1 (a) shows changes in GOT over time after administration of GA (galactosamine) when a warm water extract is administered. (b) When an ethanol extract is administered, it shows the change in GOT over time after GA administration.
【図２】（ａ）温水抽出物を投与した場合、ＧＡ投与後
の経過時間に伴なうＧＰＴの変化を示す。
（ｂ）エタノール抽出物を投与した場合、ＧＡ投与後の
経過時間に伴なうＧＰＴの変化を示す。FIG. 2 (a) shows the change in GPT over time after GA administration when a warm water extract is administered. (b) When an ethanol extract is administered, it shows the change in GPT over time after GA administration.
【図３】（ａ）温水抽出物を投与した場合、ＧＡ投与後
の経過時間に伴なうＡＬＰ活性の変化を示す。
（ｂ）エタノール抽出物を投与した場合、ＧＡ投与後の
経過時間に伴なうＡＬＰ活性の変化を示す。FIG. 3 (a) shows changes in ALP activity over time after GA administration when a warm water extract is administered. (b) When an ethanol extract is administered, it shows the change in ALP activity over time after GA administration.
【図４】（ａ）温水抽出物を投与した場合、ＧＡ投与後
の経過時間に伴なうＬＣＡＴ活性値の変化を示す。FIG. 4 (a) shows the change in LCAT activity value over time after GA administration when a warm water extract is administered.
【図５】（ａ）温水抽出物を投与した場合、ＧＡ投与４
８時間後の肝ミクロソームＰ−４５０を示す。FIG. 5: (a) GA administration 4 when hot water extract was administered.
Liver microsomal P-450 after 8 hours is shown.
【図６】（ａ）温水抽出物を投与した場合、ＧＡ投与４
８時間後のチロシントランスアミナーゼ（ＴＴＡ）活性
を示す。FIG. 6: (a) GA administration 4 when hot water extract was administered.
Tyrosine transaminase (TTA) activity after 8 hours is shown.
＊、＊＊及び＊＊＊は、ＩＩ群との次のような有意差を
示す。
＊ Ｐ＜０．０５
＊＊ Ｐ＜０．０１
＊＊＊ Ｐ＜０．００１*, **, and *** indicate the following significant differences from Group II. * P<0.05 ** P<0.01 *** P<0.001
Claims (2)
合溶液を抽出溶媒として抽出した茶抽出物を有効成分と
する、肝機能障害予防剤。1. An agent for preventing liver dysfunction, which contains as an active ingredient a tea extract obtained by extracting tea leaves using water, alcohol, or a mixed solution thereof as an extraction solvent.
合溶液を抽出溶媒として抽出した茶抽出物を含有せしめ
てなる、肝機能障害予防作用を有する機能性食品。2. A functional food having a preventive effect on liver dysfunction, which contains a tea extract obtained by extracting tea leaves using water, alcohol, or a mixed solution thereof as an extraction solvent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP03091074A JP3130327B2 (en) | 1991-03-29 | 1991-03-29 | Liver dysfunction preventive agent and functional food having hepatic dysfunction preventive action |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP03091074A JP3130327B2 (en) | 1991-03-29 | 1991-03-29 | Liver dysfunction preventive agent and functional food having hepatic dysfunction preventive action |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH04300836A true JPH04300836A (en) | 1992-10-23 |
| JP3130327B2 JP3130327B2 (en) | 2001-01-31 |
Family
ID=14016361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP03091074A Expired - Fee Related JP3130327B2 (en) | 1991-03-29 | 1991-03-29 | Liver dysfunction preventive agent and functional food having hepatic dysfunction preventive action |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3130327B2 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001076580A1 (en) * | 2000-04-11 | 2001-10-18 | Takara Bio Inc. | Remedies |
| JP2004180535A (en) * | 2002-11-29 | 2004-07-02 | Kao Corp | Method for decaffeinating caffein-containing catechin composition |
| JP2006503896A (en) * | 2002-10-23 | 2006-02-02 | クエルセジーン ホールディングス エルエルシー | Composition for improving physical ability |
| WO2008010620A1 (en) * | 2006-07-21 | 2008-01-24 | Ben's Lab Co., Ltd. | Composition comprising the crude drug extracts for improving liver function |
| JP2009057365A (en) * | 2007-08-07 | 2009-03-19 | Nippon Yakuyo Shokuhin Kenkyusho:Kk | Bowel motion-enhancing action and pancreatic lipase-inhibiting action ingredient of tea flower and its application |
| JP2009274969A (en) * | 2008-05-13 | 2009-11-26 | Kao Corp | Serum triglyceride concentration-reducing agent |
| US7883734B2 (en) | 2002-10-28 | 2011-02-08 | Kao Corporation | Method of removing caffeine from caffeine-containing catechin compound composition |
| US8088429B2 (en) | 2003-12-02 | 2012-01-03 | Kao Corporation | Package drink |
-
1991
- 1991-03-29 JP JP03091074A patent/JP3130327B2/en not_active Expired - Fee Related
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001076580A1 (en) * | 2000-04-11 | 2001-10-18 | Takara Bio Inc. | Remedies |
| JP2006503896A (en) * | 2002-10-23 | 2006-02-02 | クエルセジーン ホールディングス エルエルシー | Composition for improving physical ability |
| JP2006507283A (en) * | 2002-10-23 | 2006-03-02 | クエルセジーン ホールディングス エルエルシー | Antioxidant composition |
| JP2011157366A (en) * | 2002-10-23 | 2011-08-18 | Quercegen Holdings Llc | Composition for enhancing physical performance |
| US7883734B2 (en) | 2002-10-28 | 2011-02-08 | Kao Corporation | Method of removing caffeine from caffeine-containing catechin compound composition |
| US8574655B2 (en) | 2002-10-28 | 2013-11-05 | Kao Corporation | Packaged beverage with caffeine-containing catechin composition |
| US9198946B2 (en) | 2002-10-28 | 2015-12-01 | Kao Corporation | Green tea extract |
| JP2004180535A (en) * | 2002-11-29 | 2004-07-02 | Kao Corp | Method for decaffeinating caffein-containing catechin composition |
| US8088429B2 (en) | 2003-12-02 | 2012-01-03 | Kao Corporation | Package drink |
| WO2008010620A1 (en) * | 2006-07-21 | 2008-01-24 | Ben's Lab Co., Ltd. | Composition comprising the crude drug extracts for improving liver function |
| JP2009057365A (en) * | 2007-08-07 | 2009-03-19 | Nippon Yakuyo Shokuhin Kenkyusho:Kk | Bowel motion-enhancing action and pancreatic lipase-inhibiting action ingredient of tea flower and its application |
| JP2009274969A (en) * | 2008-05-13 | 2009-11-26 | Kao Corp | Serum triglyceride concentration-reducing agent |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3130327B2 (en) | 2001-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5538611B2 (en) | Maillard reaction inhibitor | |
| JP5937596B2 (en) | Urushi extract with increased content of active flavonoid compound and method for producing the same | |
| JP2008526737A (en) | Compositions containing gramineous plant extracts and their use for the prevention and treatment of ischemic and degenerative brain diseases | |
| RU2699011C2 (en) | Pharmaceutical composition containing silybin and l-carnitine | |
| CA3128310A1 (en) | Coronavirus therapeutic agent including elaeocarpus sylvestris extract as active ingredient | |
| KR100834348B1 (en) | Composition comprising the extracts of dictyota coriaceum for prevention and treatment of cardiovascular dyscrasia | |
| WO2007001080A1 (en) | Beverage/food and pharmaceutical comprising loquat leaf extract | |
| WO2008018142A1 (en) | Antioxidant composition containing component originating in the bark of tree belonging to the genus acacia | |
| JP3130327B2 (en) | Liver dysfunction preventive agent and functional food having hepatic dysfunction preventive action | |
| JP3334725B2 (en) | Accelerator for reducing alcohol in the body, its metabolites and oral freshener | |
| KR20210002378A (en) | Hepatoprotective composition containing pini pollen extract as effective component | |
| WO2005094858A1 (en) | Antidiabetic composition | |
| JPH06183985A (en) | Preventive and therapeutic agent for bone resorption disease | |
| JP7350304B2 (en) | Allergic rhinitis symptom suppressant | |
| JP3455436B2 (en) | How to make antioxidants | |
| JP2005047818A (en) | Health food and health drink | |
| JP2003095965A (en) | Hypertension-preventing and treating medicine | |
| JP2010043036A (en) | Saccharometabolism promoter | |
| KR102451161B1 (en) | Composition for the Improvement and Protection of Liver Health Comprising Extract of Hibiscus Syriacus | |
| KR0179088B1 (en) | Composition containing rhodiola sachalinesis extract for prophylaxis and treatment of diabetes mellitus | |
| KR20050107362A (en) | Health improving food containing an extract of the root bark of ulmus davidiana var | |
| KR102054129B1 (en) | A composition comprising extracts of Safflower seed and Korean dandelion for preventing or treating cognitive dysfunction | |
| KR20170005873A (en) | Oral composition for improving systemic symptoms including sensitivity to cold | |
| KR0179087B1 (en) | Composition containing rhodiola sachalinesis extract for lowering blood alcohol concentration | |
| KR101752476B1 (en) | A process for purifying procyanidins from extract of Lindera obtusiloba Blume |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071117 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071117 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081117 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081117 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081117 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081117 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091117 Year of fee payment: 9 |
|
| LAPS | Cancellation because of no payment of annual fees |